SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 56.61-0.6%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: dalroi who wrote (7546)12/18/2002 9:39:19 PM
From: Vector1  Read Replies (1) of 52153
 
I hope so Stefaan, the following is an excerp from a Goldman Sachs report published today.

Although the potential launch of Bexxar in 1H2003 could raise the competition for Zevalin, we
believe that the increased promotion on radioimmunotherapy by GlaxoSmithKline (GSK) could
expand the market. Some of the hurdles impeding rapid penetration of Zevalin have been the low
awareness among cancer doctors about the benefit of radioimmunotherapy and the logistical
barriers associated with nuclear medicine. GSK should help to overcome these hurdles, which are
not product specific. Therefore, we consider a positive outcome on the Bexxar review neutral to
IDEC.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News